SCYNEXIS INC Contracts & Agreements
114 Contracts & Agreements
- Business Finance (42 contracts)
- Business Operations (18)
- Human Resources (21)
- Intellectual Property (11)
- Uncategorized (22)
- Controlled Equity OfferingSM Sales Agreement, dated November 6, 2024, between SCYNEXIS, Inc. and Cantor Fitzgerald & Co (Filed With SEC on November 6, 2024)
- Employment Agreement, dated November 15, 2017, between SCYNEXIS, Inc. and Scott Sukenick (Filed With SEC on May 8, 2024)
- Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 8, 2024)
- Non-Employee Director Compensation Policy (Filed With SEC on March 28, 2024)
- Binding Memorandum of Understanding for Amendment to Exclusive License Agreement and Transitional Manufacturing and Supply Agreement, dated as of December 26, 2023, by and between... (Filed With SEC on March 28, 2024)
- Amendment to Termination and License Agreement, dated December 3, 2014, between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on November 13, 2023)
- Second Amendment to Termination and License Agreement" b/w the Company and Merck Sharp & Dohme (Filed With SEC on November 13, 2023)
- Third Amendment to Termination and License Agreement" b/w Company and Merck Sharp & Dohme Corp. (Merck), dated January 5, 2018 (Filed With SEC on November 13, 2023)
- Payoff Letter with Hercules Capital, Inc. dated May 25, 2023 (Filed With SEC on August 14, 2023)
- Amended and Restated 2015 Inducement Award Plan (Filed With SEC on November 9, 2022)
- Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the Amended and Restated 2015 Inducement Award Plan (Filed With SEC on November 9, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on August 15, 2022)
- Employment Agreement, effective May 10, 2021, between SCYNEXIS, Inc. and Christine Coyne (Filed With SEC on May 12, 2022)
- Equity Underwriting Agreement, dated April 22, 2022, by and between the Company and Guggenheim Securities, LLC, as representative of the several underwriters named on Schedule I... (Filed With SEC on April 22, 2022)
- Form of Warrant (Filed With SEC on April 22, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on April 22, 2022)
- Description of Common Stock (Filed With SEC on March 29, 2022)
- Form of Restricted Stock Unit Grant Notice and Award Agreement (Filed With SEC on February 8, 2022)
- Loan and Security Agreement, dated May 13, 2021, among the Company, Hercules Capital Inc., and Silicon Valley Bank (Filed With SEC on August 16, 2021)
- Non-employee Director Compensation Policy (Filed With SEC on August 16, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated May 17, 2021, between SCYNEXIS, Inc. and Cantor Fitzgerald & Co (Filed With SEC on May 18, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated May 17, 2021, between SCYNEXIS, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on May 18, 2021)
- Exclusive License and Collaboration Agreement, made as of February 11, 2021, by and between SCYNEXIS, Inc., Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh... (Filed With SEC on May 17, 2021)
- Master Services Agreement, effective as of February 4, 2021, by and between SCYNEXIS, Inc. and Amplity, Inc (Filed With SEC on May 17, 2021)
- Description of Common Stock (Filed With SEC on March 29, 2021)
- Fourth Amendment to Termination and License Agreement between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. dated December 2, 2020 (Filed With SEC on March 29, 2021)
- Equity Underwriting Agreement, dated December 17, 2020, by and between the Company and Guggenheim Securities, LLC, as representative of the several underwriters named on Schedule... (Filed With SEC on December 18, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on December 18, 2020)
- Form of Series 1 and Series 2 Warrant (Filed With SEC on December 18, 2020)
- SCYNEXIS, Inc. Amended and Restated Stock Plan (Filed With SEC on August 10, 2020)
- SCYNEXIS, Inc. Amended and Restated 2009 Stock Option Plan (Filed With SEC on August 10, 2020)
- SCYNEXIS, Inc. Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on August 10, 2020)
- SCYNEXIS, Inc. Amended and Restated 2014 Employee Stock Purchase Plan (Filed With SEC on August 10, 2020)
- SCYNEXIS, Inc. Amended and Restated 2015 Inducement Plan (Filed With SEC on August 10, 2020)
- Registration Rights Agreement, dated April 10, 2020, between SCYNEXIS, Inc. and Aspire Capital Fund, LLC (Filed With SEC on April 13, 2020)
- Common Stock Purchase Agreement, dated April 10, 2020, between SCYNEXIS, Inc. and Aspire Capital Fund, LLC (Filed With SEC on April 13, 2020)
- Senior Convertible Note Purchase Agreement, dated as of April 9, 2020, among SCYNEXIS, Inc., as Issuer, Puissance Life Science Opportunities Fund IV, as the Investor, (including... (Filed With SEC on April 9, 2020)
- Description of Common Stock (Filed With SEC on March 11, 2020)
- Underwriting Agreement, dated December 10, 2019, by and between the Company and H.C. Wainwright & Co., LLC, as representative of the several underwriters named on Schedule I... (Filed With SEC on December 12, 2019)
- Form of Warrant (Filed With SEC on December 12, 2019)
- SCYNEXIS, Inc. 2015 Inducement Award Plan, Adopted March 26, 2015, Amended June 9, 2015, and form of Stock Option Grant Notice and Stock Option Agreement (Filed With SEC on August 7, 2019)
- SCYNEXIS, INC., as Issuer, AND Puissance Life Science Opportunities Fund VI, as the Investor Senior Convertible Note Purchase Agreement Dated as of March 7, 2019 6.0% Convertible... (Filed With SEC on May 8, 2019)
- Second Amendment to Loan and Security Agreement between SCYNEXIS, Inc. and Solar Capital Ltd. dated March 30, 2018 (Filed With SEC on March 14, 2019)
- Non-Employee Director Compensation Arrangements (Filed With SEC on March 14, 2019)
- Senior Convertible Note Purchase Agreement, dated as of March 7, 2019, among SCYNEXIS, Inc., as Issuer, Puissance Capital Management, as the Investor, (including the form of Note... (Filed With SEC on March 8, 2019)
- Agreement pursuant to the Technology Business Tax Certificate Transfer Program (Filed With SEC on January 8, 2019)
- Third Amendment to License Agreement between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. dated December 21, 2016 (Filed With SEC on May 8, 2018)
- First Amendment to Loan and Security Agreement between SCYNEXIS, Inc. and Solar Capital Ltd. dated March 30, 2018 (Filed With SEC on May 8, 2018)
- Non-Employee Director Compensation Arrangements (Filed With SEC on March 13, 2018)
- Equity Underwriting Agreement, dated March 6, 2018, by and between the Company and Guggenheim Securities, LLC, as representative of the several underwriters named on Schedule I... (Filed With SEC on March 7, 2018)
- Form of Warrant (Filed With SEC on March 7, 2018)
- Amendment to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed With SEC on November 7, 2017)
- Additional Agreement No. 2 to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed With SEC on November 7, 2017)
- Additional Agreement No. 3 to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed With SEC on November 7, 2017)
- SECOND AMENDMENT TO TERMINATION AND LICENSE AGREEMENT (Filed With SEC on March 13, 2017)
- Executive OfficerTitle BonusMarco Taglietti, M.D.Chief Executive Officer$210,100David Angulo, M.D.Chief Medical Officer$136,600Eric FrancoisChief Financial Officer$113,000 (Filed With SEC on March 13, 2017)
- AMENDMENT TO COMMITMENT TO SERVICES AGREEMENT (Filed With SEC on March 13, 2017)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on October 5, 2016)
- WARRANT TO PURCHASE STOCK (Filed With SEC on October 5, 2016)
- 9,375,000 Shares of Common Stock ($0.001 Par Value) Warrants to Purchase up to 4,218,750 Shares of Common Stock SCYNEXIS, Inc. Common Stock EQUITY UNDERWRITING AGREEMENT (Filed With SEC on June 22, 2016)
- SCYNEXIS, INC. Warrant to Purchase Common Stock (Filed With SEC on June 22, 2016)
- 101 Hudson Street, Suite 3610 " Jersey City, NJ 07302, USA " TEL: 201 ###-###-#### " FAX: 201 ###-###-#### (Filed With SEC on May 9, 2016)
- 101 Hudson Street, Suite 3610 " Jersey City, NJ 07302, USA " TEL: 201 ###-###-#### " FAX: 201 ###-###-#### (Filed With SEC on May 9, 2016)
- SCYNEXIS, INC. Up to$40,000,000 Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on April 11, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on March 7, 2016)
- COMMITMENT TO SERVICES AGREEMENT (Filed With SEC on November 13, 2015)
- NameTitleRoleSeth GoldblumManaging DirectorProject OversightRob RostronDirectorDeep Dive & Project ManagementJon WoodallDirectorFull Time Project Execution as Interim Chief... (Filed With SEC on November 13, 2015)
- RELEASE AND SETTLEMENT AGREEMENT (Filed With SEC on August 19, 2015)
- ASSET PURCHASE AGREEMENT BY AND BETWEEN ACCURATUS LAB SERVICES, INC. (Buyer) AND SCYNEXIS, INC.(Seller) July 17, 2015 TABLE OF CONTENTS (Filed With SEC on July 23, 2015)
- [] Shares SCYNEXIS, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENT (Filed With SEC on April 20, 2015)
- SCYNEXIS, INC. 2015INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 (Filed With SEC on April 9, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on March 30, 2015)
- RESEARCH SERVICES AGREEMENT (Filed With SEC on March 30, 2015)
- EXCLUSIVE LICENSE AGREEMENT BETWEEN WATERSTONE PHARMACEUTICAL (HK) LIMITED AND SCYNEXIS, INC. DATED AS OF October 29, 2014 (Filed With SEC on March 30, 2015)
- COMPENSATION ARRANGEMENT WITH NON-EMPLOYEE DIRECTORS (Filed With SEC on March 3, 2015)
- COMPENSATION ARRANGEMENT WITH NON-EMPLOYEE DIRECTORS (Filed With SEC on December 3, 2014)
- SCYNEXIS, Inc. Non-Employee Director Compensation Policy (Filed With SEC on August 13, 2014)
- SCYNEXIS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 EFFECTIVE DATE: February 11, 2014 (Filed With SEC on April 30, 2014)
- SCYNEXIS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 (Filed With SEC on April 30, 2014)
- SCYNEXIS, Inc. Description of Non-Employee Directors CompensationProgram (Filed With SEC on April 30, 2014)
- SCYNEXIS, Inc. 3501-CTriCenter Blvd Durham, NC 27713 April 9, 2010 (Filed With SEC on April 30, 2014)
- FORM OF INDEMNIFICATIONAGREEMENT (Filed With SEC on March 19, 2014)
- SCYNEXIS, INC. 2009STOCK OPTION PLAN (Filed With SEC on March 19, 2014)
- SCYNEXIS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 EFFECTIVE DATE: February 11, 2014 (Filed With SEC on March 19, 2014)
- SCYNEXIS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 (Filed With SEC on March 19, 2014)
- SCYNEXIS, Inc. Description of Non-Employee Directors CompensationProgram (Filed With SEC on March 19, 2014)
- DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BETWEEN R-PHARM, CJSC AND SCYNEXIS, INC. DATED AS OF August 1st, 2013 (Filed With SEC on March 19, 2014)
- LICENSE AGREEMENT (Filed With SEC on March 19, 2014)
- TERMINATION AND LICENSE AGREEMENT (Filed With SEC on March 19, 2014)
- Dated 10 June 2005 (1) SCYNEXIS, Inc. -and - (2) C-CHEM AG Agreement forthe Assignment of Patents and Know How concerning Cyclosporin Derivatives 1 (Filed With SEC on March 19, 2014)
- RESEARCH SERVICES AGREEMENT (Filed With SEC on March 19, 2014)
- Dated May 10, 2005 (1) Aventis Pharma S.A. - and - (2) SCYNEXIS,Inc. Exclusive World-wide Licence Agreement (Filed With SEC on March 19, 2014)
- GuaranteeExtension Agreement (Filed With SEC on March 19, 2014)
- AMENDED and RESTATED LICENSE, DEVELOPMENT & COMMERCIALIZATION AGREEMENT Between SCYNEXIS, Inc. And ELANCOANIMAL HEALTH, a division of ELI LILLY AND COMPANY (Filed With SEC on March 19, 2014)
- SCYNEXIS, INC. SERIESC-2 PREFERRED STOCK PURCHASE AGREEMENT (Filed With SEC on March 19, 2014)
- SCYNEXIS, Inc. 3501-CTriCenter Blvd Durham, NC 27713 April 9, 2010 (Filed With SEC on March 19, 2014)
- [] Shares SCYNEXIS, Inc. Common Stock ($0.001 Par Value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on February 27, 2014)
- SCYREX, INC. STOCKOPTION PLAN (Filed With SEC on February 27, 2014)
- SCYNEXIS, INC. 2009STOCK OPTION PLAN (Filed With SEC on February 27, 2014)
- SCYNEXIS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 EFFECTIVE DATE: February 11, 2014 (Filed With SEC on February 27, 2014)
- SCYNEXIS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11,2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 (Filed With SEC on February 27, 2014)
- SCYNEXIS, Inc. Description of Non-Employee Directors Compensation Program (Filed With SEC on February 27, 2014)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 27, 2014)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 27, 2014)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 27, 2014)
- LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- TERMINATION AND LICENSE AGREEMENT (Filed With SEC on February 27, 2014)
- Dated 10 June 2005 (1) SCYNEXIS, Inc. -and - (2) C-CHEM AG Agreement forthe Assignment of Patents and Know How concerning Cyclosporin Derivatives 1 (Filed With SEC on February 27, 2014)
- RESEARCH SERVICES AGREEMENT (Filed With SEC on February 27, 2014)
- Dated May 10, 2005 (1) Aventis Pharma S.A. - and - (2) SCYNEXIS,Inc. Exclusive World-wide Licence Agreement (Filed With SEC on February 27, 2014)
- AMENDMENT 1 TO THEEXCLUSIVE WORLD-WIDE LICENSE AGREEMENT ENTERED INTO BY AND BETWEEN SCYNEXIS Inc and AVENTIS PHARMA S.A. ON MAY THE 10th, 2005 (Filed With SEC on February 27, 2014)
- REIMBURSEMENT AGREEMENT; GENERALSECURITY AGREEMENT (Filed With SEC on February 27, 2014)
- GuaranteeExtension Agreement (Filed With SEC on February 27, 2014)
- SCYNEXIS, INC. FIFTHAMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT SCYNEXIS, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on February 27, 2014)
